Galecto Inc (GLTO) - Total Liabilities
Based on the latest financial reports, Galecto Inc (GLTO) has total liabilities worth $25.18 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore how much of Galecto Inc's assets are long-term investments to see how much of total assets are deployed in long-term investments.
Galecto Inc - Total Liabilities Trend (2018–2025)
This chart illustrates how Galecto Inc's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see balance sheet size of Galecto Inc.
Galecto Inc Competitors by Total Liabilities
The table below lists competitors of Galecto Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Chinese Universe Publishing And Media Co Ltd
SHG:600373
|
China | CN¥10.15 Billion |
|
Capital Southwest Corporation
NASDAQ:CSWC
|
USA | $1.26 Billion |
|
Aerospace Nanhu Electronic Information Technology Co. Ltd. A
SHG:688552
|
China | CN¥882.76 Million |
|
Aygaz AS
IS:AYGAZ
|
Turkey | TL12.66 Billion |
|
Wealthfront Corporation Common Stock
NASDAQ:WLTH
|
USA | $1.01 Billion |
|
Deutsche EuroShop AG
F:DEQ
|
Germany | €2.70 Billion |
|
Lotus Pharmaceutical Co Ltd
TW:1795
|
Taiwan | NT$84.28 Billion |
|
Tong Yang Industry Co Ltd
TW:1319
|
Taiwan | NT$8.58 Billion |
Liability Composition Analysis (2018–2025)
This chart breaks down Galecto Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See GLTO equity financing ratio to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 22.48 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.05 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.05 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Galecto Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Galecto Inc (2018–2025)
The table below shows the annual total liabilities of Galecto Inc from 2018 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $20.15 Million | +1448.58% |
| 2024-12-31 | $1.30 Million | -77.93% |
| 2023-12-31 | $5.90 Million | -48.44% |
| 2022-12-31 | $11.44 Million | +129.07% |
| 2021-12-31 | $4.99 Million | -18.26% |
| 2020-12-31 | $6.11 Million | -24.96% |
| 2019-12-31 | $8.14 Million | +83.12% |
| 2018-12-31 | $4.44 Million | -- |
About Galecto Inc
Damora Therapeutics, Inc., a clinical-stage biotechnology company, develops molecule therapeutics for the treatment of fibrosis, cancer, inflammation, and other related diseases. It develops GB3226, a preclinical small molecule dual inhibitor of ENL-YEATS and FLT3 and GB1211, an oral small molecule inhibitor of galectin-3 to treat multiple types of oncology and liver disease indications. The comp… Read more